Michael Friedländer

63.4k total citations · 14 hit papers
493 papers, 27.5k citations indexed

About

Michael Friedländer is a scholar working on Oncology, Reproductive Medicine and Genetics. According to data from OpenAlex, Michael Friedländer has authored 493 papers receiving a total of 27.5k indexed citations (citations by other indexed papers that have themselves been cited), including 274 papers in Oncology, 235 papers in Reproductive Medicine and 149 papers in Genetics. Recurrent topics in Michael Friedländer's work include Ovarian cancer diagnosis and treatment (225 papers), BRCA gene mutations in cancer (131 papers) and PARP inhibition in cancer therapy (121 papers). Michael Friedländer is often cited by papers focused on Ovarian cancer diagnosis and treatment (225 papers), BRCA gene mutations in cancer (131 papers) and PARP inhibition in cancer therapy (121 papers). Michael Friedländer collaborates with scholars based in Australia, United States and United Kingdom. Michael Friedländer's co-authors include David W. Hedley, Ian W. Taylor, Elizabeth A. Musgrove, Catherine A. Rugg, M. William Audeh, Ursula A. Matulonis, James Carmichael, Clare L. Scott, David Goldstein and Matthew C. Kiernan and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Michael Friedländer

474 papers receiving 26.8k citations

Hit Papers

Method for analysis of cellular DNA content of paraffin-e... 1983 2026 1997 2011 1983 2010 2012 2010 2014 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.
    1983 1.8k citations Michael Friedländer et al. profile →
  2. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
    2010 1.7k citations James Carmichael, Michael Friedländer et al. profile →
  3. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
    2012 1.3k citations Jonathan A. Ledermann, Philipp Harter et al. profile →
  4. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
    2010 1.3k citations Michael Friedländer, Mark Wickens et al. profile →
  5. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
    2014 1.2k citations Bella Kaufman, Ronnie Shapira‐Frommer et al. Journal of Clinical Oncology profile →
  6. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
    2014 1.1k citations Jonathan A. Ledermann, Philipp Harter et al. profile →
  7. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
    2012 853 citations Anna DeFazio, Penelope M. Webb et al. Journal of Clinical Oncology profile →
  8. Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
    2013 558 citations Susanna B. Park, David Goldstein et al. profile →
  9. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
    2009 500 citations Michael A. Bookman, Mark F. Brady et al. Journal of Clinical Oncology profile →
  10. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
    2011 452 citations Ignace Vergote, Éric Pujade-Lauraine et al. profile →
  11. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
    2014 426 citations Amit M. Oza, Nicoletta Colombo et al. profile →
  12. The importance of patient-reported outcomes in clinical trials and strategies for future optimization
    2018 372 citations Michael Friedländer et al. profile →
  13. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
    2016 309 citations Jonathan A. Ledermann, Philipp Harter et al. profile →
  14. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
    2021 255 citations Michael Friedländer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Friedländer Australia 73 15.7k 9.8k 7.5k 5.2k 4.6k 493 27.5k
Ursula A. Matulonis United States 77 13.4k 0.9× 8.2k 0.8× 7.9k 1.1× 2.7k 0.5× 3.1k 0.7× 443 23.1k
Karen H. Lu United States 72 6.8k 0.4× 8.3k 0.8× 7.4k 1.0× 3.9k 0.8× 4.8k 1.0× 427 21.6k
Robert L. Coleman United States 72 7.7k 0.5× 9.5k 1.0× 7.7k 1.0× 1.6k 0.3× 3.5k 0.8× 690 23.3k
Andrew Berchuck United States 73 5.8k 0.4× 6.9k 0.7× 8.1k 1.1× 2.9k 0.6× 3.8k 0.8× 358 19.9k
Douglas A. Levine United States 70 6.7k 0.4× 7.3k 0.7× 9.3k 1.2× 2.0k 0.4× 6.3k 1.4× 256 22.4k
Steven A. Narod Canada 99 14.1k 0.9× 7.0k 0.7× 12.1k 1.6× 20.0k 3.8× 12.5k 2.7× 703 41.1k
Frédéric Amant Belgium 66 7.2k 0.5× 9.0k 0.9× 3.7k 0.5× 1.5k 0.3× 3.2k 0.7× 554 21.9k
Maurie Markman United States 63 6.4k 0.4× 7.9k 0.8× 4.3k 0.6× 1.1k 0.2× 2.7k 0.6× 417 19.9k
David M. Gershenson United States 76 5.2k 0.3× 12.0k 1.2× 4.2k 0.6× 1.4k 0.3× 2.3k 0.5× 406 21.6k
Jalid Sehouli Germany 65 5.9k 0.4× 7.8k 0.8× 5.8k 0.8× 1.0k 0.2× 3.2k 0.7× 866 19.2k

Countries citing papers authored by Michael Friedländer

Since Specialization
Citations

This map shows the geographic impact of Michael Friedländer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Friedländer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Friedländer more than expected).

Fields of papers citing papers by Michael Friedländer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Friedländer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Friedländer. The network helps show where Michael Friedländer may publish in the future.

Co-authorship network of co-authors of Michael Friedländer

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Friedländer. A scholar is included among the top collaborators of Michael Friedländer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Friedländer. Michael Friedländer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ngoi, Natalie Y.L., Chel Hun Choi, Diana Lim, et al.. (2025). Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial. Clinical Cancer Research. 31(18). 3907–3915. 2 indexed citations
2.
3.
Li, Tiffany, Hui‐Ming Lin, Hannah C. Timmins, et al.. (2024). Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy. JCO Precision Oncology. 8(8). e2300690–e2300690. 1 indexed citations
4.
Woodford, Rachel, Peey‐Sei Kok, Sarah J. Lord, et al.. (2024). Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials. JCO Precision Oncology. 8(8). e2300296–e2300296. 1 indexed citations
5.
Majidi, Azam, Renhua Na, Susan J. Jordan, et al.. (2023). Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study. JNCI Journal of the National Cancer Institute. 115(5). 570–577. 6 indexed citations
6.
7.
Friedländer, Michael, Linda Mileshkin, Janine Lombard, et al.. (2023). Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. British Journal of Cancer. 129(5). 797–810. 9 indexed citations
8.
Konstantinopoulos, Panagiotis A., Antonio González-Martı́n, Felipe Melo Cruz, et al.. (2022). EPIK-O/ENGOT-OV61: Alpelisib Plus Olaparib vs Cytotoxic Chemotherapy in High-Grade Serous Ovarian Cancer (Phase III Study). Future Oncology. 18(31). 3481–3492. 16 indexed citations
9.
You, Benoît, Vasudha Sehgal, Balakrishna Hosmane, et al.. (2022). CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. Journal of Clinical Oncology. 41(1). 107–116. 20 indexed citations
10.
Goldstein, David, Hannah C. Timmins, Tiffany Li, et al.. (2022). Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study. Journal of Translational Medicine. 20(1). 564–564. 6 indexed citations
11.
Woodford, Rachel, Peey‐Sei Kok, Sarah J. Lord, et al.. (2022). The validity of progression‐free survival 2 as a surrogate trial end point for overall survival. Cancer. 128(7). 1449–1457. 10 indexed citations
12.
Gebski, Val, et al.. (2022). Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. European Journal of Cancer. 170. 169–178. 3 indexed citations
13.
Milne, Roger L., et al.. (2021). Bilateral Salpingo-oophorectomy and Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Assessing the Evidence. Cancer Prevention Research. 14(11). 983–994. 10 indexed citations
14.
Friedländer, Michael, Sarah J. Lord, Rebecca Asher, et al.. (2021). Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer. 154. 190–200. 9 indexed citations
15.
Mazza, Danielle, Martha Hickey, Louise Keogh, et al.. (2020). Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians. JNCI Cancer Spectrum. 5(1). 3 indexed citations
16.
Phillips, Kelly‐Anne, Ian Collins, Roger L. Milne, et al.. (2016). Anti-Müllerian Hormone Serum Concentrations of Women With Germline BRCA1 or BRCA2 Mutations. Obstetrical & Gynecological Survey. 71(8). 474–475. 8 indexed citations
17.
Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2014). Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer. Obstetrical & Gynecological Survey. 69(10). 594–596. 14 indexed citations
18.
Friedländer, Michael, et al.. (2013). A Fibroid or Cancer? A Rare Case of Mixed Choriocarcinoma and Epithelioid Trophoblastic Tumour. Case Reports in Obstetrics and Gynecology. 2013. 1–2. 11 indexed citations
19.
20.
Bookman, Michael A., Mark F. Brady, William P. McGuire, et al.. (2009). Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup. Journal of Clinical Oncology. 27(9). 1419–1425. 500 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ursula A. Matulonis Breakdown of academic impact, for papers by Karen H. Lu Breakdown of academic impact, for papers by Robert L. Coleman Breakdown of academic impact, for papers by Andrew Berchuck Breakdown of academic impact, for papers by Douglas A. Levine Breakdown of academic impact, for papers by Steven A. Narod Breakdown of academic impact, for papers by Frédéric Amant Breakdown of academic impact, for papers by Maurie Markman Breakdown of academic impact, for papers by David M. Gershenson Breakdown of academic impact, for papers by Jalid Sehouli
Rankless by CCL
2026